IROMED GROUP


RESEARCH, DEVELOPMENT AND MANUFACTURING OF OPHTHALMIC MEDICAL DEVICES.

IROMED GROUP IS AN R&D AND MEDICAL DEVICES MANUFACTURING COMPANY. ITS MISSION IS TO DEVELOP UNIQUE AND INNOVATIVE OPHTHALMIC PRODUCTS AND SOLUTIONS FOR HEALTHCARE PROFESSIONALS.

edit button text.

OPHTHALMIC MEDICAL DEVICES MANUFACTURING AND R&D

IROMED GROUP IS AN R&D AND MEDICAL DEVICES MANUFACTURING COMPANY. ITS MISSION IS TO DEVELOP UNIQUE AND INNOVATIVE OPHTHALMIC PRODUCTS AND SOLUTIONS FOR HEALTHCARE PROFESSIONALS.

Iromed Group develops and manufactures ophthalmic medical devices. Thanks to its strong commitment to research, Iromed develops unique and innovative ophthalmic technologies, formulations, and protocols. All Iromed products are supported by international patents and publications in top-ranked scientific journals.

Iromed Group is in partnership with SERVImed Industrial S.p.A., which manages the worldwide distribution of its products through Italian and international companies, providing continuous support to its clients. 

 

OUR OPHTHALMIC PRODUCT LINES:

  • CORNEAL CROSS-LINKING: IROMED GROUP produces a complete CXL line of CE marked Medical Devices:
    • CF X-LINKER ®, a UV device that provides high flexibility in corneal ectasias treatment, by selecting the proper treatment depending on both patients’ and doctors’ needs, while introducing its own innovative customized protocol, an EPI-ON low power procedure with clinical 7-year follow-up, published on Cornea.
    • Patented solutions based on riboflavin and Vitamin E TPGS (RIBOCROSS ® te and RIBOFAST) with high performances, for every CXl protocol and with a wide range of UV devices on the market. IROMED GROUP's solutions are the only ones suited for Custom Fast CXL protocol.

 

  • EYE DROPS: IROMED GROUP manufactures ophthalmic solutions with patented formulations, covering a wide range of applications:
    • DROP defence ® is the first and only PPE certified solution with anti-UV and anti-blue light shielding effect;
    • DROP therapeutic ® is a high-quality artificial tear, used in many applications, like dry eye, pre/post-cross-linking, and surgical procedures to accelerate epithelial regeneration;
    • DROPsept ® is an ophthalmic solution with phlogolithic action, adjuvant in protecting and repairing corneal and conjunctival epithelium;
    • DROPclar ® is an antioxidant ophthalmic solution.

 

  • DIAGNOSTICS: IROMED GROUP produces ophthalmic Diagnostic Medical Devices:
    • REmark ® is the first and only riboflavin based diagnostic solution, alternative to fluorescein, that can be used in tonometry, and general surface diagnosis.

 

  • DIETARY SUPPLEMENTS: IROMED GROUP produces unique dietary supplements for eye health:
    • MACUoff ® is a dietary supplement with anti-angiogenic and anti-oxidant effects.

MILESTONES:

 

2014: Launch of the Ophthalmic R&D division 

IROMED Group opens its own R&D division to start researching ophthalmic products. The company’s objective is to develop and bring to the market innovative, unique and patented products and formulations with strong scientific backing.

The development of the R&D department benefited from its research experience and the continuous support of clinical research and international publications in high impact journals. All of IROMED Group’s ophthalmic products are patented and CE marked.

 

2016: RIBOCROSS ® te on the market

In 2016, RIBOCROSS ® te, the first cross-linking solution based on Riboflavin and Vitamin E TPGS, is launched globally.
Developed with a high corneal penetration and patented formulation, RIBOCROSS ® te is the only solution that uses Vitamin E TPGS’ enhancer properties to provide high performances in every corneal cross-linking protocol. RIBOCROSS ® te is the only Riboflavin solution that can be used in the exclusive Custom fast CXL protocol.

 

2017: CF X-LINKER ® system launch 

In 2017, IROMED Group’s Ophthalmic surgical line expands with the international launch of CF X-LINKER ®, a versatile UV device for corneal cross-linking, bringing to the market the Custom Fast CXL, a customized low power EPI-ON protocol, unique to the CF X-LINKER ® device.

 

2018: RIBOFAST and DROP defence ® on the market

The cross-linking line expands with the addition of RIBOFAST, a patented dextran free solution that makes IROMED Group’s cross-linking portfolio one of the most versatile on the market.

In the same year, the eye drops line is officially opened with the launch of DROP defence ®, an anti-UV and anti-blue light protective solution, which is the first and only solution to receive the Personal Protective Equipment certification.

 

2019: growing portfolio

2019 is a year of much growth for our ophthalmic portfolio, with the launch of two new products: DROP therapeutic ®, a high quality patented solution, and DROPsept ®, a unique and patented solution with protective and repairing action.

In the same year, IROMED Group announces a partnership with TECLens for the distribution and FDA approval of a new combined product for keratoconus treatment, solidifying its international status.